Bimagrumab

{
  "id": "MLC-T-ONC-012014",
  "term": "Bimagrumab",
  "field": "Oncology and biomedicine",
  "definition": "A human monoclonal antibody directed against type II activin receptors (ActRII; ActR2), with potential muscle-sparing and anti-cachectic activities. Upon administration, bimagrumab binds to ActRII, which prevents the binding of the natural ligands, myostatin and activin, to activin receptors and blocks ActRII-mediated signaling. This increases protein synthesis, decreases protein degradation, stimulates skeletal muscle cell growth, and increases muscle function and strength. Overstimulation of the ActRII-mediated signaling pathway is associated with muscle loss and weakness.",
  "synonyms": [
    "human combinatorial antibody library-based monoclonal antibody BYM338",
    "HuCAL-based antibody BYM338"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/bimagrumab/"
}